The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses

Journal of General Virology

Volumn 79, Issue 10, 1998, Pages 2381-2391

  Hultgren, Catharina ^a   Milich, David R ^b   Weiland, Ola ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 4; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY;

ANIMALIA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; MURINAE;

EID: 0031663638     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-79-10-2381     Document Type: Article

References (46)

1. Agbaria, R., Mullen, C. A., Hartman, N. R., Cooney, D. A., Hao, Z., Blaese, R. M. & Johns, D. G. (1994). Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. Molecular Pharmacology 45, 777-782.
2. American Academy of Pediatrics Committee on Infectious Diseases (1996). Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97, 137-140.
3. Balzarini, J., Lee, C. K., Herdewijn, P. & De Clercq, E. (1991). Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 266, 21509-21514.
4. Connor, E., Morrison, S., Lane, J., Oleske, J., Sonke, R. L. & Connor, J. (1993). Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 37, 532-539.
5. Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C. R. & Murphy, B. R. (1994). Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. Journal of Virology 68, 5321-5325.
6. Di Bisceglie, A. M., Shindo, M., Fong, T. L., Fried, M. W., Swain, M. G., Bergasa, N. V., Axiotis, C. A., Waggoner, J. G., Park, Y. & Hoofnagle, J. H. (1992). A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16, 649-654.
7. Di Bisceglie, A. M., Conjeevaram, H. S., Fried, M. W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D. E., Mahaney, K. & Hoofnagle, J. H. (1995). Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 123, 897-903.
8. Drach, J. C., Barnett, J. W., Thomas, M. A., Smith, S. H. & Shipman, C. (1980). Inhibition of viral and cellular DNA synthesis by ribavirin. In Ribavirin: A Broad Spectrum Antiviral Agent, pp. 119-128. Edited by R. A. Smith & W. Kirkpatrick. San Francisco: Academic Press.
9. Dusheiko, G., Main, J., Thomas, H., Reichard, O., Lee, C., Dhillon, A., Rassam, S., Fryden, A., Reesink, H., Bassendine, M., Norkrans, G., Cuypers, T., Lelie, N., Telfer, P., Watson, J., Weegink, C., Sillikens, P. & Weiland, O. (1996). Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology 25, 591-598.
10. Englund, J. A., Piedra, P. A., Jefferson, L. S., Wilson, S. Z., Taber, L. H. & Gilbert, B. E. (1990). High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. Journal of Pediatrics 117, 313-320.
11. Fairbanks, L. D., Bofill, M., Ruckemann, K. & Simmonds, H. A. (1995). Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. Journal of Biological Chemistry 270, 29682-29689.
12. Fried, M. W., Fong, T. L., Swain, M. G., Park, Y., Beames, M. P., Banks, S. M., Hoofnagle, J. H. & Di Bisceglie, A. M. (1994). Therapy of chronic hepatitis B with a 6-month course of ribavirin. Journal of Hepatology 21, 145-150.
13. Heagy, W., Crumpacker, C., Lopez, P. A. & Finberg, R. W. (1991). Inhibition of immune functions by antiviral drugs. Journal of Clinical Investigation 87, 1916-1924.
14. Hosoya, M., Shigeta, S., Ishii, T., Suzuki, H. & De Clercq, E. (1993). Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. Journal of Infectious Diseases 168, 641-646.
15. Hultgren, C., Milich, D. R. & Sällberg, M. (1997). Antibodies to hepatitis B e (HBeAg) can be induced in HBeAg transgenic mice by adoptive transfer of a specific T-helper 2 cell clone. Clinical and Diagnostic Laboratory Immunology 4, 630-632.
16. Japour, A. J., Lertora, J. J., Meehan, P. M., Erice, A., Connor, J. D., Griffith, B. P., Clax, P. A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D., Bassiakos, Y. & Crumpacker, C. S. (1996). A phase-1 study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13, 235-246.
17. Jiang, Z. L., Kunimoto, M. & Patel, J. A. (1998). Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. Journal of Virology 72, 2496-2499.
18. Jin, L. & Peterson, D. L. (1995). Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Archives of Biochemistry and Biophysics 323, 47-53.
19. Jin, L., Wei, X., Gomez, J., Datta, M., Birkett, A. & Peterson, D. L. (1995). Use of alpha-N,N-bis[carboxymethyl]lysine-modified peroxidase in immunoassays. Analytical Biochemistry 229, 54-60.
20. Kakumu, S., Yoshioka, K., Wakita, T., Ishikawa, T., Takayanagi, M. & Higashi, Y. (1993). Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Hepatology 18, 258-263.
21. Lai, M. Y., Kao, J. H., Yang, P. M., Wang, J. T., Chen, P. J., Chan, K. W., Chu, J. S. & Chen, D. S. (1996). Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology, 111, 1307-1312.
22. Mastronarde, J. G., Monick, M. M., Gross, T. J. & Hunninghake, G. W. (1996). Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. American Journal of Physiology 271, L201-L207.
23. Milich, D. R., McLachlan, A., Thornton, G. B. & Hughes, J. L. (1987). Immune response to hepatitis B virus core antigen HBcAg: localization of T cell recognition sites within HBcAg/HBeAg. Journal of Immunology 139, 1223-1231.
24. Milich, D. R., McLachlan, A., Stahl, S., Wingfield, P., Thornton, G. B., Hughes, J. L. & Jones, J. E. (1988). Comparative immunogenicity of hepatitis B virus core and e antigens. Journal of Immunology 141, 3617-3624.
25. Milich, D. R., Jones, J. E., Hughes, J. L., Price, J., Raney, A. K. & McLachlan, A. (1990). Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proceedings of the National Academy of Sciences, USA 87, 6599-6603.
26. Milich, D. R., McLachlan, A., Raney, A. K., Houghten, R., Thornton, G. B., Maruyama, T., Hughes, J. L. & Jones, J. E. (1991). Auto-antibody production in hepatitis B e antigen transgenic mice elicited with a self T-ceil peptide and inhibited with nonself peptides. Proceedings of the National Academy of Sciences, USA 88, 4348-4352.
27. Milich, D. R., Peterson, D. L., Schödel, F., Jones, J. & Hughes, J. L. (1995a). Preferential recognition of the hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. Journal of Virology 69, 2776-2785.
28. Milich, D. R., Schödel, F., Peterson, D. L., Jones, J. & Hughes, J. L. (1995 b). Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice. European Journal of Immunology 25, 1663-1672.
29. Milich, D. R., Wolf, S. F., Hughes, J. L. & Jones, J. J. (1995 c). Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proceedings of the National Academy of Sciences, USA 92, 6847-6851.
30. Milich, D. R., Schödel, F., Hughes, J. L., Jones, J. E. & Peterson, D. L. (1997). The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. Journal of Virology 71, 2192-2201.
31. Reichard, O., Andersson, J., Schvarcz, R. & Weiland, O. (1991). Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058-1061.
32. Reichard, O., Norkrans, G., Fryden, A., Braconier, J. H., Sonnerborg, A. & Weiland, O. (1998). Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 351, 83-87.
33. Ribavirin ARC Study Group (1993). Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 6, 32-41.
34. Rodriguez, W. J., Hall, C. B., Welliver, R., Simoes, E. A., Ryan, M. E., Stutman, H., Johnson, G., Van Dyke, R., Groothuis, J. R., Arrobio, J. and others (1994). Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. Journal of Pediatrics 125, 129-135.
35. Sällberg, M., Pushko, P., Berzinsh, I., Bichko, V., Sillekens, P., Noah, M., Pumpens, P., Grens, E., Wahren, B. & Magnius, L. O. (1993), Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences. Journal of General Virology 74, 1335-1340.
36. Sällberg, M., Zhang, Z.-X., Chen, M., Jin, L., Birkett, A., Peterson, D. L. & Milich, D. R. (1996). Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. Journal of General Virology 77, 2721-2728.
37. Sällberg, M., Townsend, K., Chen, M., O'Dea, J., Banks, T., Jolly, D. J., Chang, S. M., Lee, W. T. & Milich, D. R. (1997). Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. Journal of Virology 71, 5295-5303.
38. Schödel, F., Peterson, D., Zheng, J., Jones, J. E., Hughes, J. L. & Milich, D. R. (1993). Structure of hepatitis B virus core and e-antigen. A single precore amino acid prevents nucleocapsid assembly. Journal of Biological Chemistry 268, 1332-1337.
39. Schvarcz, R., Ando, Y., Sonnerborg, A. & Weiland, O. (1995). Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. Journal of Hepatology 23, 17-21.
40. Shigeta, S., Mori, S., Baba, M., Ito, M., Honzumi, K., Nakamura, K., Oshitani, H., Numazaki, Y., Matsuda, A., Obara, T. and others (1992). Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrobial Agents and Chemotherapy 36, 435-439.
41. Spanish Ribavirin Trial Group (1991). Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Lancet 338, 6-9.
42. Srikiatkhachorn, A. & Braciale, T. J. (1997). Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. Journal of Virology 71, 678-685.
43. Stevens, T. L., Bossie, A., Sanders, V. M., Fernandez-Botran, R., Coffman, R. L., Mossman, T. R. & Vitetta, E. S. (1988). Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334, 255-258.
44. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. & Anderson, L. J. (1996). Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Journal of Virology 70, 2852-2860.
45. Zhang, Z.-X., Chen, M., Hultgren, C., Birkett, A., Milich, D. R. & Sällberg, M. (1997 a). Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. Journal of General Virology 78, 2735-2746.
46. Zhang, Z.-X., Milich, D. R., Peterson, D. L., Birkett, A., Schvarcz, R., Weiland, O. & Sällberg, M. (1997 b). Interferon-alpha treatment induces delayed CD4+ proliferative responses to the hepatitis C virus non-structural 3 protein regardless of the outcome of therapy. Journal of Infectious Diseases 175, 1294-1301.